Biosynthesis of dTDP-6-deoxy-◆-D-allose, biochemical characterization of dTDP-4-keto-6-deoxyglucose reductase (GerK1) from *Streptomyces* sp. KCTC 0041BP

Ta Thi Thu Thuy¹, Kwangkyoung Liou¹, Tae Jin Oh¹, Doo Hyun Nam², Jin Cheol Yoo³ and Jae Kyung Sohng^{1*}

¹Institute of Biomolecule Reconstruction (iBR), SunMoon University, #100, Kalsan-ri, Tangjeong-myeon, Asansi, Chungnam 336-708, Korea. ²Department of Pharmacy, Yeungnam University, Kyungbuk, 712-749, Korea. ³Department of Pharmacy, Chosun University, Kwangju, 501-759, Korea

dTDP-6-deoxy-D-allose, an unusual deoxysugar, has been identified as an intermediate in the mycinose biosynthetic pathway of several macrolide antibiotics. In order to characterize the biosynthesis of this deoxysugar, we have cloned andheterologously overexpressed gerK1 in E. coli BL21 (DE3) cells. This gene encodes for a protein with the putative function of a dTDP-4-keto-6-deoxyglucose reductase, which appears to be involved in the dihydrochalcomycin (GERI-155) biosynthesis evidenced by Streptomyces sp KCTC 0041BP. Our results revealed that GerK1 exhibited a specific reductive effect on the 4-keto carbon of dTDP-4-keto-6-deoxyglucose, with the hydroxyl group in an axial configuration at the C3 position only. The enzyme catalyzed the conversion of dTDP-4-keto-6-deoxyglucose to dTDP-6-deoxy- Φ -D-allose, according to the results of an in vitro coupled enzyme assay, in the presence of GerF (dTDP-4-keto-6-deoxyglucose 3-epimerase). The product was isolated, and its stereochemistry was determined via NMR analysis.

Acknowledgements

This study was supported by the 21C Frontier Microbial Genomics and Application Center Program, Ministry of Science & Technology (Grant MG02-0301-004-2-3-1), Republic of Korea.